Results 41 to 50 of about 53,090 (292)

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.

PLoS ONE, 2023
T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn, Korakot Atjanasuppat, Kitipong Uaesoontrachoon, Parin Rattananon, Worapapar Treesuppharat, Suradej Hongeng, Usanarat Anurathapan   +6 more
doaj   +2 more sources

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj   +1 more source

A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay

Frontiers in Pharmacology, 2023
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu, TianDuo Wang, John A. Ronald, John A. Ronald   +3 more
doaj   +1 more source

Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression

Annals of Clinical and Translational Neurology, EarlyView.
Epigenetic reprogramming in hematopoietic stem and progenitor cells (HSPCs) and downstream myeloid cells, mediated by H3.3 downregulation and endogenous retroelement (ERE) overexpression, contributes to the progression of multiple sclerosis (MS). ABSTRACT Background Skewed myelopoiesis in the bone marrow has been identified as a key driver of multiple ...
Li‐Mei Xiao, Qiu‐Ping Zhao, Run‐Yun Li, Wei Chen, Huan‐Huan Song, Wan‐Jin Chen, Ying Fu   +6 more
wiley   +1 more source

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Frontiers in Oncology, 2022
BackgroundThe CAR T-cell therapy is a promising approach to treating hematologic malignancies. However, the application in solid tumors still has many tough challenges, including heterogenicity in antigen expressions and immunosuppressive tumor ...
Yuanyuan Liu, Yanxin Zheng, Tianyi Deng, Yue Huang, Ziwen Liu, Borui Zhan, Xusha Zhou, Runbin Yan, Jiangtao Ren, Yun Xing, Guixing Wu, Biao Zheng, Guang Hu, Wen Wang, Yonghong Liu, Jing Zhao, Xiaoqing Chen, Grace Guoying Zhou   +17 more
doaj   +1 more source

Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry, Amanda J Novak, Alexander W Rankin, Catherine Pham-Danis, Etienne Danis, M Eric Kohler   +5 more
doaj   +1 more source

Caracterização imunofenotípica de diferentes linhagens de plasmocitomas murinos utilizadas na produção de anticorpos monoclonais. – [PDF]

, 2015
TCC(graduação) - Universidade Federal de Santa Catarina. Centro de Ciências Biológicas. Biologia.Anticorpos monoclonais são importantes reagentes utilizados na pesquisa biomédica, em testes de diagnóstico, bem como no tratamento de enfermidades.
Rosa, Elis Amaral
core  

Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges

Hematology/Oncology and Stem Cell Therapy, 2022
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in ...
Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S. Majhail   +4 more
doaj   +1 more source

A Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19

Blood, 2021
Abstract Introduction: CD19-directed chimeric antigen receptor T (CART19) cell therapies have shown impressive clinical outcomes in CD19+ B-cell malignancies. All the FDA-approved CART19, including tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraucel use an anti-CD19 single-chain variable ...
Ruchi Patel, Ki-Hyun Kim, Yong Gu Lee, Puneeth Guruprasad, Soohwan Kim, Ji-Hyeon Choi, Sung-Min Kim, Gae-Baik Kim, Jong-Ho Lee, Hyun-Jong Lee, Ji-Ho Park, Guewha Lee, LeiGuang Cui, Min Yoon, Ki Hyun Kim, Soohyun Kim, In-Sik Hwang, Youngha Lee, Jong Seo Lee, Junho Chung, Marco Ruella   +20 more
openaire   +1 more source

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source